NCT02253927View on ClinicalTrials.gov

Dose Escalation Study of Pharmacokinetics, Safety and Tolerability After Single Dose Administration of BILR 355 (SDS) Plus Low-dose Ritonavir in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

May 31, 2006

Primary Completion Date

August 31, 2006

Conditions
Healthy
Interventions
DRUG

BILR 355 - D1

DRUG

BILR 355 - D2

DRUG

BILR 355 - D3

DRUG

BILR 355 - D4

DRUG

Ritonavir

OTHER

high fat breakfast

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY

NCT02253927 - Dose Escalation Study of Pharmacokinetics, Safety and Tolerability After Single Dose Administration of BILR 355 (SDS) Plus Low-dose Ritonavir in Healthy Volunteers | Biotech Hunter | Biotech Hunter